

INFECTIOUS DISEASE TESTS



**Precise diagnosis.
Accurate treatment.**

LABSYSTEMS
DIAGNOSTICS
speaking your language



Labsystems Diagnostics Oy

WHO WE ARE

Labsystems Diagnostics Oy is a Finnish establishment, a forerunner in innovative In Vitro Diagnostic research and development for 34 years. Around 50 experienced professionals work at the modern facilities in Helsinki area in Finland. Labsystems Diagnostics' products are sold throughout the world.

WHAT WE DO

Labsystems Diagnostics develops, manufactures, markets and sells high quality diagnostic tests for clinical laboratories, doctors' offices and home use. Through the changes in ownerships, the latest merger of Ani Labsystems Ltd. Oy and Ani Biotech Oy and acquisition by the globally-operating, India-based Trivitron Healthcare Group, the company has achieved many milestones.

Labsystems Diagnostics has a strong experience in the infectious disease tests over the decades. We were among the first ones to create EIA tests on a microplate format and to create EIA tests based on peptide technology. We now produce well recognised high quality EIA tests especially for respiratory infections.

Under the Biocard™ Point-of-Care brand, we have developed first and only tests suitable for fingertip blood for detecting Chlamydia Pneumoniae and Mycoplasma Pneumoniae. Biocard™ is a trademark listed in the Master lists of the College of American Pathologists (CAP) Proficiency testing (PT). In addition to this, convenient duplex real-time PCR tests have been launched.

Gastro and Cardiac POC tests are also manufactured under the Biocard™ brand. Labsystems Diagnostics was the first to create a newborn screening test in high -throughput format and is now the second most important manufacturer of newborn screening tests worldwide.

EIA TESTS

- Best performer assays supported by internal and external quality monitoring and by international evaluations
- Used as a preferred method by well-established clinical and research laboratories
- Flexibility to use in different automated and manual systems
- Qualitative and Semi-Quantitative results
- Ready-to-use components
- Easy multiplexing due to similar test procedures, and interchangeable buffers and substrates
- Individually coded removable strips give further convenience in test combinations
- IgG absorbent included in ready-to use reagents in IgM kit- no separate reagents or steps are needed
- Long stability for opened components (6 months)



MIFA TESTS

- Gold standard method for *C.pneumoniae* serology
- Internal and external quality monitoring
- High density of Elementary Bodies for easy reading
- LPS eliminated to give species-specific results
- *C.trachomatis* and *C.psittaci* control spots
- IgG Blocking reagent available



DUPLEX REAL-TIME PCR TESTS

- Individual and simultaneous identification and quantification of the two infectious agents
- All-in-one amplification mix, including internal genomic DNA control
- No freeze storage required as the entire kit can be stored at +4°C; Shipment at room temperature
- Suitable for instruments with universal fluorescence channels
- High sensitivity (down to 10 copies/ml) and specificity (no cross reactions detected)
- High quality controlled by internal and external QC samples



POINT-OF CARE TESTS

- Biocard™ test line*
- Lateral flow tests
- Results in 5 to 10 minutes with easy 2-step procedure
- Results can be obtained during the doctor's appointment
- No instrumentation is needed: all the accessories for sampling and running the test are included
- No venipuncture and serum separation is needed (in the blood tests) as tests can be done directly from the fingertip blood
- Flexibility to use either serum or whole blood samples
- Storage at room temperature, no cold room is needed and product is ready to use at any moment



*Trademark listed in the Master list of the CAP Proficiency Test. (www.cap.org)

Products	Assay Platforms						
	EIA	MIFA	qPCR	POC	Test/pack	Cat. No	Advantage
CHLAMYDIA PNEUMONIAE IgG EIA	x				96	6111300	LPS eliminated to give species-specific results Higher throughput compared to MIFA
CHLAMYDIA PNEUMONIAE IgA EIA	x				96	6111310	
CHLAMYDIA PNEUMONIAE IgM EIA	x				96	6111320	
C. PNEUMONIAE IgG/IgM MIFA		x			20x12	6108382	High density of Elementary Bodies for easy reading
C. PNEUMONIAE IgA MIFA		x			20x12	6108392	LPS eliminated to give species-specific results
MYCOPLASMA PNEUMONIAE IgG EIA	x				96	6111400	Excellent performance against PCR results Accurate results guaranteed by P1-antigen
MYCOPLASMA PNEUMONIAE IgA EIA	x				96	6111410	
MYCOPLASMA PNEUMONIAE IgA EIA	x				96	6111420	
BIOCARD™ C.PNEUMONIAE IgM				x (cass.)	10	3-034-000	Results can be obtained during a doctor's appointment All the accessories for the sampling and testing included
BIOCARD™ M. PNEUMONIAE IgM				x (cass.)	20	3-035-000	
C. pneumoniae and M. pneumoniae Duplex Real-Time PCR			x		25	8100100	Individual and simultaneous identification of the two bacteria No freeze storage is required Fast, down to 35 min
C. pneumoniae and M. pneumoniae Duplex Real-Time PCR			x		100	8100100	
C. pneumoniae and M. pneumoniae Duplex Real-Time PCR			x		150	8100101	
BORDETELLA PERTUSSIS IgG EIA	x				96	6111500	Whole cell antigen High accuracy demonstrated in WHO reference laboratory
BORDETELLA PERTUSSIS IgA EIA	x				96	6111510	
BORDETELLA PERTUSSIS IgM EIA	x				96	6111520	
BORDETELLA PERTUSSIS PT IgG EIA	x				96	6111530	Quantitative anti-PT test according to ECDC recommendation, calibrated against WHO standard

Products	Assay Platforms						
	EIA	MIFA	qPCR	POC	Test/pack	Cat. No	Advantage
B. pertussis and B. parapertussis Duplex Real-Time PCR			x		25	8100200	Individual and simultaneous identification of the two bacteria No freeze storage is required Fast, down to 35 min
B. pertussis and B. parapertussis Duplex Real-Time PCR			x		100	8101200	
BIOCARD™ Strep A Test				x (stick)	20	3-017-420	Highly sensitive test for detection of group A Streptococci from throat swab Positive control included
CHLAMYDIA TRACHOMATIS IgG EIA	x				96	6111101	For complicated and prolonged infections Species-specific peptide antigens guarantee high accuracy
CHLAMYDIA TRACHOMATIS IgA EIA	x				96	6111111	
TOXOPLASMA GONDII IgG EIA	x				96	6600100	Quantitative IgG test standardized against WHO reference μ-capture IgM test, no need for separate IgG removing step; Similar protocols for IgG and IgM
TOXOPLASMA GONDII IgM EIA	x				96	6600120	
TOXOPLASMA GONDII IgG AVIDITY	x				24	6600140	Avidity template provided for the calculation of the avidity % and interpretation
BIOCARD™Parvo B 19 Test				x (cass.)	10	3-031-000	For testing the acute phase of the disease Results can be obtained during a doctor's appointment All the accessories for the sampling and testing included Tests can be done directly from the fingertip blood sample but also intravenous blood or serum can be used Only test available for whole blood
BIOCARD™Rotastick Test				x (stick)	20	3-006-420	Test for detection of rotavirus from faecal swab sample Positive control included Use unique combination of highly specific antibodies to accurately detect the rotavirus antigen

Tests are manufactured in Finland, CE marked (C.pneumoniae through Notified Body audit)



Labsystems Diagnostics Oy
Tiilitie 3, FI-01720 Vantaa, Finland


Contact us:

Tel.: +358 20 155 7530

For price and dealer queries: sales@labsystemsdx.com

For technical information: support@labsystemsdx.com

Official Labsystems Diagnostics Partner/Distributor:



www.labsystemsdx.com